Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage treatment. Rituximab-based chemoimmunotherapy regimens (e.g., R-DHAP, R-ICE, R-ESHAP) are the conventional standard of care for R/RDLBCL followed by conditioning and autologous or allogeneic stem cell transplantation (SCT) in eligible patients. The anti-CD19 CAR T-cell therapies Yescarta (Gilead/Kite) and Kymriah (Novartis) have expanded treatment options for patients with DLBCL, although their current use is restricted to third and subsequent lines of therapy. Despite the evolving market landscape, significant unmet need remains in the treatment of R/RDLBCL due to the limited availability of effective treatment options.
- What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/R DLBCL?
- How do current therapies perform on key clinical attributes for R/R DLBCL?
- What are the major unmet needs and the most lucrative opportunities in R/R DLBCL?
- When considering new treatment options in this setting, what trade-offs are acceptable to surveyed hematologist-oncologists between key clinical attributes and cost of therapy?
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. hematologist-oncologists and 30 European hematologist-oncologists.
Key companies: Gilead, Kite Pharma, Novartis, Roche / Genentech.
Key drugs: Rituximab, Yescarta, Kymriah.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
- Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Unmet Need - Detailed, Expanded Analysis: Relapsed Or Refractory DLBCL - (US-EU)
Author(s): Sudha Malhotra, Ph.D; Sorcha Cassidy M.Res., Ph.D
Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.
Sorcha Cassidy M.Res., Ph.D., is an Associate Director in the Oncology team at Decision Resources Group. Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an M.Res and Ph.D in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.